
Native Microbials
Novel microbial community screening methods to discover, develop, and commercialise next generation feed additives.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor | €0.0 | round |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
* | $1.4m | Grant | |
Total Funding | 000k |
Related Content
Native Microbials, Inc., established in 2015, operates within the animal health and nutrition sector, focusing on the development and commercialization of microbial supplements for livestock. The company was co-founded by CEO Mallory Embree and Chief Scientific Officer Michael F. Fischbach, who leveraged their deep backgrounds in microbiology and chemistry to address animal health challenges. Fischbach, a professor at Stanford University's Department of Bioengineering, and Embree, who holds a PhD in Chemistry from the University of California, Berkeley, initiated their collaboration to apply advanced microbiome science to practical agricultural applications.
The firm's core business revolves around creating next-generation feed additives that utilize a proprietary platform to analyze the native microbial ecosystems of animals. By identifying specific microbes that are naturally present in high-performing animals, Native Microbials isolates, preserves, and scales these organisms for broader application. This approach aims to enhance the health, productivity, and sustainability of livestock, particularly dairy cows and cattle. The primary clients are farmers and large-scale agricultural operations seeking to improve animal digestion, nutrient absorption, and overall well-being, which can translate into greater feed efficiency and productivity.
Native Microbials' product lineup, including Galaxis and Rumeni, is delivered as a liquid feed supplement that is mixed directly into the total mixed ration for livestock. These products are designed to introduce beneficial, naturally-occurring microbes into the animal's digestive system to optimize its function. The company's business model is based on the sale of these microbial products to the agricultural industry. A significant milestone was achieved in 2021 when the company secured an oversubscribed $100 million Series B financing round, indicating strong investor confidence in its scientific platform and market strategy.
Keywords: animal microbiome, microbial supplements, livestock nutrition, agricultural biotechnology, dairy health, cattle feed additives, microbiome science, animal health, agtech, feed efficiency